Type1Screen (Australia)
Royal Melbourne Hospital / Walter and Eliza Hall Institute (supported by Breakthrough T1D Australia)
What it is
Australia's national islet-autoantibody screening program, coordinated from Royal Melbourne Hospital, offering free in-home finger-prick blood-spot testing. The current funder page offers screening to anyone in Australia over age 1, extending beyond the relatives studied in the published cohort. Positive results lead to confirmation, staging and monitoring.
Editorial review: .
Most recent recorded citation date: 2025-01-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Predictive value: In-home blood-spot screening identified the expected 2.1% prevalence of multiple islet autoantibodies in family members; two or more autoantibodies reliably mark near-certain progression to clinical T1D.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 84 × 25 + 80 × 25 + 80 × 20 + 85 × 15 + 65 × 15 = 7950; divide by total weight 100. Unrounded weighted result: 79.5.
In-home blood-spot screening identified the expected 2.1% prevalence of multiple islet autoantibodies in family members; two or more autoantibodies reliably mark near-certain progression to clinical T1D.[1]
Among 2-year participants, all 12 who developed clinical diabetes had screened positive and none presented with DKA — the core actionable benefit — and screen-positives can access monitoring and disease-modifying therapy.[1]
The current programme description offers free screening to anyone in Australia over age 1, not only relatives. The published two-year outcomes came from a family-history cohort, so its yield should not be assumed for a general-population programme.[3]
A free in-home capillary finger-prick blood spot returned by post, well suited to younger and regionally located participants; only the small screen-positive minority need confirmatory venous testing.[1]
Free home screening for anyone in Australia over age 1, now advertised beyond relatives. Positive results require clinical follow-up; access to disease-modifying treatment depends on stage, age and funding.[2]
The full picture
Current access (16 September 2026): Breakthrough T1D Australia’s programme page now offers free screening to anyone in Australia over age 1. The published outcomes below describe the earlier relatives cohort, rather than the yield expected in the wider population. https://breakthrought1d.org.au/news/type1screen-for-t1d/
Type1Screen is Australia's islet-autoantibody screening program, coordinated from Royal Melbourne Hospital with the Walter and Eliza Hall Institute and supported by Breakthrough T1D Australia. It now offers free testing to anyone in Australia over age 1, with two explicit aims: prevent diabetic ketoacidosis (DKA) at diagnosis and enable use of disease-modifying therapy once a person is found to be progressing.
The headline advance is convenience. Since 2022, Type1Screen has offered an in-home capillary finger-prick dried blood spot that families collect and post back, instead of a clinic venous draw. In its 2-year outcomes, most registrants chose the blood spot, and the option drew in more younger and regional participants — exactly the people a clinic-only model tends to miss. Blood-spot screening identified the expected 2.1% prevalence of multiple islet autoantibodies, the marker of near-certain future T1D.
The results show why early detection matters: in the published 2-year follow-up, of the 12 participants who went on to develop clinical diabetes, all had screened positive and none presented in DKA. Coordinated through five pediatric centers across the mainland states, the program has national reach and is building the laboratory infrastructure for eventual population-level screening. This wider offer is not yet a universal screening service embedded in routine Australian care.
What's next for this
- →Scale-up of laboratory infrastructure toward national population-level screening and a planned general-population pilot in Australia
Sources
- [1]Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen · Peer-reviewed study · 2025-01-01
- [2]
- [3]